Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% ...

Vertex Pharmaceuticals Inc (VRTX) reports a 3% revenue increase, driven by US growth and new product launches, despite ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.06 per share, missing the Zacks Consensus Estimate of $4.22 per share. This compares to earnings of $4.76 per share a year ago.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, ...

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CEO Reshma Kewalramani highlighted the company’s strong performance in Q1 2025, with $2.77 billion in revenue, representing a 3% year-over-year increase. Growth was driven by expanding patient reach ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported first-quarter profit of $646.3 million. On a per-share basis, the Boston-based company said it had net income of $2.49 ...

The stock's fall snapped a seven-day winning streak.

Vertex Pharmaceuticals Inc (NASDAQ: VRTX) reported first-quarter results that fell short of analyst expectations, sending ...